文献速递前列腺癌

早期前列腺癌主动监测中活检分级分组进展后未治疗的自然史与延迟根治性治疗

The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
PubMed 文献 · J Urol · 2022-01-04

基于1990-2018年前瞻性主动监测队列,531例活检分级分组1级后升级至≥2级并继续监测的患者中,40%未治疗,36%接受早期根治性前列腺切除术,24%接受延迟根治性前列腺切除术。早期与延迟根治性前列腺切除术在分级分组、不良病理率(55% vs 53%)及3年无复发生存率(80% vs 87%)上无显著差异。

要点

  • 活检进展后继续主动监测者中,60%在5年内接受手术。
  • 早期与延迟根治性前列腺切除术的不良病理率分别为55%与53%,无显著差异。
  • 早期与延迟根治性前列腺切除术的3年无复发生存率分别为80%与87%,无显著差异。

核心结论

  • 活检进展后延迟手术与不良病理或无复发生存风险升高无关,提示部分患者或可安全延迟治疗。

研究设计与样本

  • 前瞻性主动监测队列(1990-2018年),纳入分级分组1级、局限期前列腺癌、前列腺特异抗原<20且随后升级至≥2级并继续监测的患者531例。

主要发现

  • 531例活检进展并继续监测的患者中,214例(40%)未治疗,192例(36%)接受早期根治性前列腺切除术,125例(24%)接受延迟根治性前列腺切除术。
  • 早期与延迟根治性前列腺切除术组的分级分组无差异(p=0.15),不良病理率分别为55%与53%(p=0.74),无显著差异。
  • 早期与延迟根治性前列腺切除术组的3年无复发生存率分别为80%与87%(log-rank p=0.64),无显著差异。
  • 多变量模型中,仅癌症前列腺风险评术后评分与无复发生存风险相关(HR=1.42每分,95%CI 1.24-1.64)。

临床怎么用

  • 作者认为,活检进展后部分经过选择的患者或可安全延迟治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For men with clinically localized prostate cancer outcomes of continuing active surveillance (AS) after biopsy progression are not well understood. We aim to determine the impact of continuing AS and delayed definitive treatment after biopsy progression on oncologic outcomes. MATERIALS AND METHODS: Participants in our prospective AS cohort (1990-2018) diagnosed with grade group (GG) 1, localized prostate cancer, with prostate specific antigen <20 who were subsequently upgraded to ≥GG2, and underwent further surveillance (biopsy/imaging/prostate specific antigen) were identified. Patients were stratified by post-progression followup into 3 groups: continue AS untreated, pursue early radical prostatectomy (RP) ≤6 months, or undergo late RP within 6 months to 5 years of progression. Patients receiving other treatments were excluded. We compared characteristics between groups and examined the associations of early vs late RP with risk of adverse pathology (AP) at RP and recurrence-free survival (RFS) after RP. RESULTS: Of 531 patients with biopsy progression and further surveillance 214 (40%) remained untreated, 192 (36%) pursued early RP and 125 (24%) underwent late RP. Among patients who underwent early vs late RP, there was no difference in GG (p=0.15) or AP (55% vs 53%, p=0.74) rate at RP, or 3-year RFS (80% vs 87%, log-rank p=0.64) after RP. In multivariable models, only Cancer of Prostate Risk Assessment post-surgical score was associated with risk of RFS (HR=1.42 per point, 95% CI 1.24-1.64). CONCLUSIONS: Among patients continuing AS after biopsy progression, 60% underwent surgery within 5 years. Delayed surgery after progression was not associated with higher risk of AP or RFS. This suggests select patients may be able to safely delay treatment after progression.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chappidi MR, Bell A, Cowan JE, et al. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. J Urol. 2022. PMID: 34981949. doi:10.1097/JU.0000000000002420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。